货号：AB9244

品牌：Merck Millipore

规格：EA

目录价：询价

金山科研平台，产品价格货期咨询微信：jinshanbio Description: Anti-Parkin Antibody | AB9244 View All» Promotional Text: Special Shipping Offer on Antibodies100% Performance Guaranteed View All» Trade Name: Chemicon (Millipore) View All» Specificity: Parkin View All» Immunogen: Synthetic peptide from mouse Parkin. View All» Species Reactivity:

• Bovine

• Human

• Mouse

• Monkey

• Rat
  View All» Application Notes: Western blotting: 1:1,000-1:2,000 Immunocytochemistry: 1:1,000 Optimal working dilutions must be determined by the end user. View All» Control: POSITIVE CONTROLS: HEK293, SH-SY5Y and COS7 cells. View All» Presentation: Affinity purified immunoglobulin. Liquid in PBS containing 0.02% sodium azide. View All» Storage Conditions: Maintain at -20°C to -80°C in undiluted aliquots for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles. View All» UniProt Number: O60260 View All» Entrez Gene Number:
  • NM_004562.1

  • NM_013987.1

  • NM_013988.1
    View All» Gene Symbol:
    • PARK2

    • PDJ

    • PRKN

    • LPRS2

    • AR-JP

    • parkin

    • EC 6.3.2.-
      View All» Usage Statement: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. View All» Key Applications:
      • ELISA

      • Western Blotting

      • Immunocytochemistry

      • Immunohistochemistry
        View All» Entrez Gene Summary: The precise function of this gene is unknown; however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in this gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support. View All» UniProt Summary: FUNCTION: SwissProt: O60260 # Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP and SEPT5. May play a more general role in the ubiquitin proteasomal pathway by participating in the removal and/or detoxification of abnormally folded or damaged protein. Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin E during neuronal apoptosis. May represent a tumor suppressor gene.SIZE: 465 amino acids; 51641 Da SUBUNIT: Forms an E3 ubiquitin ligase complex with UBE2L3 or UBE2L6. Part of a SCF-like complex, consisting of PARK2, CUL1 and FBXW7. Interacts with SNCAIP. Binds to the C2A and C2B domains of SYT11. Interacts and regulates the turnover of SEPT5. Part of a complex, including STUB1, HSP70 and GPR37. The amount of STUB1 in the complex increases during ER stress. STUB1 promotes the dissociation of HSP70 from PARK2 and GPR37, thus facilitating PARK2-mediated GPR37 ubiquitination. HSP70 transiently associates with unfolded GPR37 and inhibits the E3 activity of PARK2, whereas, STUB1 enhances the E3 activity of PARK2 through promotion of dissociation of HSP70 from PARK2-GPR37 complexes. Interacts with PSMD4 and PACRG. Interacts with LRRK2. Interacts with RANBP2. Interacts with SUMO1 but not SUMO2, which promotes nuclear localization and autoubiquitination.SUBCELLULAR LOCATION: Cytoplasm. Note=Co-localizes with STY11 in neutrites. Co-localizes with SNCAIP in brainstem Lewy bodies. Nucleus.TISSUE SPECIFICITY: Highly expressed in the brain including the substantia nigra. Expressed in heart, testis and skeletal muscle. Expression is down-regulated or absent in tumor biopsies, and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis.DOMAIN: SwissProt: O60260 The ubiquitin-like domain binds the PSMD4 subunit of 26S proteasomes.PTM: Auto-ubiquitinates in an E2-dependent manner leading to its own degradation. & S-nitrosylated. The inhibition of PARK2 ubiquitin E3 ligase activity by S-nitrosylation could contribute to the degenerative process in PD by impairing the ubiquitination of PARK2 substrates.DISEASE: SwissProt: O60260 # Defects in PARK2 are a cause of Parkinson disease (PD) [MIM:168600]. PD is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early- onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology of PD involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. & Defects in PARK2 are the cause of autosomal recessive early onset Parkinson disease 2 (PARK2) [MIM:600116]; also known as early-onset parkinsonism with diurnal fluctuation (EPDF) or autosomal recessive juvenile Parkinson disease (PDJ). PARK2 is symptomatically different in several aspects from idiopathic Parkinson disease, although classic symptoms such as bradykinesia, rigidity and tremor are present. Additional clinical features include early DOPA-induced dyskinesia, diurnal fluctuation of the symptoms, sleep benefit, dystonia and hyper-reflexia. PARK2 is usually characterized by onset before 40, with a mean age at onset of 23.2 years. Pathologically, PARK2 patients show loss of dopaminergic neurons in the substantia nigra, similar to that seen in Parkinson disease; however, Lewy bodies (intraneuronal accumulations of aggregated proteins) are absent. & Defects in PARK2 may be involved in the development and/or progression of ovarian cancer.SIMILARITY: Contains 2 IBR-type zinc fingers. & Contains 2 RING-type zinc fingers. & Contains 1 ubiquitin-like domain.MISCELLANEOUS: The parkin locus (PRKN), adjacent to the 6q telomere is hyper-recombinable and lies within FRA6E, the third most common fragile site in tumor tissue. View All» Brand Family: Chemicon View All» Product Name: Anti-Parkin Antibody | AB9244 View All» Concentration: 1 mg/mL View All» Antibody Type: Polyclonal Antibody View All» Qty/Pk: 100 µg View All» Format: Affinity Purified View All» Host: Rabbit View All»
        © 金山科研平台是专业的授权总代理区域代理经销平台。
        © 如需询价，请加客服QQ：1749072012 、客服微信：jinshanbio，或发送邮件到1749072012@qq.com
        © 平台为生命科学研究相关领域提供一站式耗材试剂仪器解决方案和采购服务，数据资源基于CC协议。
        © 本文地址：https://www.16ao.com/thread-158479.htm
        © Merck Millipore代理AB9244 PARKIN, RBX-100UG;已停产，产品报价联系微信jinshanbio